HC Wainwright & Co. Reiterates Buy on Protara Therapeutics, Maintains $23 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Protara Therapeutics (NASDAQ:TARA) and maintained a price target of $23.
August 04, 2023 | 3:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Protara Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $23.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for Protara Therapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100